Advertisement

Verfahren zur Inaktivierung von Viren in Plasma und Plasmaderivaten — gegenwärtiger Kenntnisstand und künftige Entwicklungen

  • U. T. Seyfert
  • W. Hauck
  • M. Köhler
  • E. Wenzel
Conference paper

Zusammenfassung

Die meisten durch Bluttransfusionen oder nach Gabe von Plasmaprodukten verursachten Todesfälle sind auch heute noch auf die Übertragung infektiöser Agentien zurückzuführen.

Ein Maßnahmenkatalog zur Verbesserung der „Virussicherheit“ von Plasma und Plasmaprodukten wird vorgestellt:

Neben einer adäquaten Indikationsstellung sind sorgfältige Spenderauswahl und eine suffiziente Labordiagnostik erforderlich. Effiziente Verfahren zur Viruselimination und Virusinaktivierung müssen weiter verbessert werden. Eine Produktbeobachtungspflicht („postmarketing surveillance“) auch nach klinischem Einsatz eines Blutproduktes ist erforderlich, um rechtzeitig negative Auswirkungen auf die Reinheit, Wirksamkeit, Unbedenklichkeit und Verträglichkeit zu erkennen.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Alter HJ, Creagan RP, Morel PA (1988) Photochemical decontamination of blood components containing hepatitis B and non-A, non-B virus. Lancet 2: 1446–1450.PubMedCrossRefGoogle Scholar
  2. Andreu G, Boccaccio C, Lecrubier C (1990) UV irradiation of platelet concentrates: feasibility in transfusion practice. Transfusion 30: 401–406.PubMedCrossRefGoogle Scholar
  3. Aronson DL (1990) The development of the technology and capacity for the production of factor VIII for the treatment of hemophilia. Transfusion 30: 748–758.PubMedCrossRefGoogle Scholar
  4. Björkander J, Cunningham-Rundles C, Lundin P (1988). IV Immunglobulin prophylaxis causing liver damage in 16 of 77 patients with hypogammaglobulinemia. Am J Med 84: 107–111.PubMedCrossRefGoogle Scholar
  5. Brackmann HH, Egli H (1988) Acute hepatitis B infection after treatment with heat inactivated factor VIII concentrate. Lancet ii: 967.CrossRefGoogle Scholar
  6. Bradley D, Maynard J, Popper H (1983) Post Transfusion non-A, non-B hepatitis. J Infect Dis 148: 254–265.PubMedCrossRefGoogle Scholar
  7. Brand A, van Rood JJ, Claas FHJ (1989) UV-irradiated platelets: ready to use? Transfusion 29: 377–378.PubMedCrossRefGoogle Scholar
  8. Braunstein AH, Obermann HA (1984) Transfusion of plasma components. Transfusion 24: 281–286.PubMedCrossRefGoogle Scholar
  9. Brettler DB, Levine PH (1989) Factor concentrates for treatment of hemophilia: which one to choose? Blood 73: 2067–2073.PubMedGoogle Scholar
  10. o’Brien JM, Sieber F (1989) Mutagenicity of merocyanine 540 — mediated photosensitization. Exp. Hematol 17: 166–170.Google Scholar
  11. Chernoff AI, Klein HG, Sherman LA (1989) Research opportunities in transfusion medicine. Transfusion 29: 711–742.CrossRefGoogle Scholar
  12. Clifton CE (1931) Photodynamic action of certain dyes on the inactivation of staphylococcus bacteriophage. Proc Soc Exp Biol Med 28: 745–746.CrossRefGoogle Scholar
  13. Cole M, Stromberg R, Friedman L (1989) Photochemical inactivation of virus in red cells. Transfusion 29: 145 — abstr.Google Scholar
  14. Colombo M, Camelli V, Gazengel C (1985). Transmission of Non-A Non-B hepatitis by heat treated factor VIII concentrate. Lancet ii: 1–4.CrossRefGoogle Scholar
  15. Colombo M, Morfini M, Mannucci PM (1990) Virus inactivation in clotting factor concentrates. Transf Sci 11: 43–49. REVIEWCrossRefGoogle Scholar
  16. Deeg HJ (1989) Transfusions with a tan. Transfusion 29: 450–454.PubMedCrossRefGoogle Scholar
  17. Dietrich SL, Mosley JW, Lusher JM (1990) Transmission of HIV-1 by dry heated clotting factor concentrates. Vox Sang 59: 129–135.PubMedCrossRefGoogle Scholar
  18. Dupont WD (1990) Power and sample size calculations. Controlled Clinical Trials 11: 116–129.PubMedCrossRefGoogle Scholar
  19. Eckstein R (1988) Bluttransfusion und Infektionskrankheiten. In: Fortbildungsprogramm Serologie/Immunologie 1988, Biotest, Berlin 5.5.1988, S. 1–47.Google Scholar
  20. Einarsson M, Perenius L, Cort S (1989) Heat inactivation of human immunodeficiency virus in solutions of antithrombin III. Transfusion 29: 148–152.PubMedCrossRefGoogle Scholar
  21. Emmons RW (1988) Ecology of Colorado tick fever. Ann Rev Microbiol 42: 49–64.CrossRefGoogle Scholar
  22. Farber EM, Abel EA, Cox AJ (1983) Long term risks of psoralen and UV therapy for psoriasis. Arch Dermatol 119: 426–431.PubMedCrossRefGoogle Scholar
  23. Fratantoni JC, Prodouz KN, Horowitz MS (1990) Viral inactivation of blood products. Transfusion 30: 480–481.PubMedCrossRefGoogle Scholar
  24. Goldmann M (1991) Blood product associated bacterial sepsis. Transf Med Rev 5: 73–83.CrossRefGoogle Scholar
  25. Gregersen JP, Hilfenhaus J, Lemp JF (1989) Heat inactivation of HIV-2. J Biol Standard 17: 377–379.CrossRefGoogle Scholar
  26. Hiemstra H, Tersmette M, Vos AHV (1991) Inactivation of HIV by gamma radiation and its effect on plasma and coagulation factors. Transfusion 31: 32–39.PubMedCrossRefGoogle Scholar
  27. Horowitz B, Wiebe M, Lippin A (1985) Inactivation of viruses in labile blood derivatives. Transfusion 25: 516–527.PubMedCrossRefGoogle Scholar
  28. Horowitz B, Piet MPJ, Prionce AM (1988) Inactivation pf lipid enveloped viruses in labile blood derivatives by unsatturated fatty acids. Vox Sang 54: 14–20.PubMedCrossRefGoogle Scholar
  29. Horowitz MS, Horowitz B, Hilgartner MW (1988) Virus safety of S/D treated antihemophilic factor concentrate. Lancet ii: 186–188.CrossRefGoogle Scholar
  30. Horowitz B (1989) Investigations into the application of Tri(n-butyl)phosphate/detergent mixtures to blood derivatives. In: Morgenthaler JJ (ed.) Virus inactivation in plasma products. Curr Stud Hematol Blood Transf 56: 83–96.Google Scholar
  31. Horowitz B, Williams B, Rywkin S (1991) Inactivation of viruses in blood with aluminium phthalocyanine derivatives. Transfusion 31: 102–108.PubMedCrossRefGoogle Scholar
  32. Hudson JB, Towers GN (1988) Antiviral properties of photosensitizers. Photochem Photobiol 48: 289–296.PubMedCrossRefGoogle Scholar
  33. Johnson BH, Johnson MA, Moore MA (1977). Psoralen — DNA photoreaction. Science 197: 906–908.PubMedCrossRefGoogle Scholar
  34. Katzenelson E, Kletter B, Shuval HI (1974) Inactivation kinetics of viruses and bacteria in water by use of ozone. J Am Water Works Ass 66: 725–729.Google Scholar
  35. Kitchen AD, Mann CF, Harrison JF (1989) Effect of gamma irradiation on the human immundeficiency virus and human coagulation proteins. Vox Sang 56: 233–229.Google Scholar
  36. Kiyosawa K, Sodeyama T, Alter HJ (1990) Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma. Hepatology 12: 671–675.PubMedCrossRefGoogle Scholar
  37. Kleim JP, Bailly E, Schneeweis KE, Brackmann HH (1990) Acute HIV-1 infection in patients with hemophilia B treated with β-propiolactone-UV-inactivated clotting factor. Thromb Hemostas 64: 336–337.Google Scholar
  38. Lane RJM, Dick JPR, Belleroche J (1991) Glycone and neurodegenerative disease. Lancet 337: 732–733.PubMedCrossRefGoogle Scholar
  39. Lane RS (1983) Non-A, Non-B hepatitis from iv immunoglobulins. Lancet ii: 974–975.CrossRefGoogle Scholar
  40. Lever AML, Webszter ADB, Brown D (1984) Non-A Non-B hepatitis occuring in agamma-globulinemic patients after iv immunoglobulin. Lancet ii: 1062–1064.CrossRefGoogle Scholar
  41. Lin L, Wiesehahn GP, Morel PA (1989) Use of 8-methoxypsoralen and long wavelength uv radiation for decontamination of platelet concentrates. Blood 74: 517–529.PubMedGoogle Scholar
  42. Lusher JM, Salzman PM (1990) Viral safety and inhibitor development associated with factor VIIIC ultra-purified from plasma in hemophiliacs previously unexposed to factor VIII C Concentrates. Sem Hematol 27: 1–7.Google Scholar
  43. Lytle CD, Carney PG, Feiten RP (1989) Inactivation and mutagenesis of herpes virus by photodynamic treatment with therapeutic dyes. Photochem Pathobiol 50: 367–371.Google Scholar
  44. Mannucci PM, Colombo M (1988) Virucidal treatment of clotting factor concentrates. Lancet i: 782–785 (1988).CrossRefGoogle Scholar
  45. Mannucci PM, Zanetti AR, Colombo M (1988) Prospective study of hepatitis after factor VIII concentrate exposed to hot vapour. Brit J Haematol 68: 427–430.CrossRefGoogle Scholar
  46. Mannucci PM, Colombo M (1989) Revision of the protocol recommended for studies of safety from hepatitis of clotting factor concentrates. Thromb Haemostas 61: 532–534.Google Scholar
  47. Mannucci PM, Zanetti AR, Colombo M (1990) Antibody to hepatitis C virus after a vapour heated factor VIII concentrate. Thromb Haemostas 64: 232–234.Google Scholar
  48. Matthews JL, Newman JT, Songandares-Bernal F (1988) Photodynamic therapy of viral contaminants with potential for blood banking applications. Transfusion 28: 81–83.PubMedCrossRefGoogle Scholar
  49. Mollison PL, Engelfriet CP, Conreras M (1987) Blood transfusion in clinical Medicine. Blackwell Scientific Publications, Oxford.Google Scholar
  50. Morey AL, Nicolini U, Welch CR (1991) Parvovirus B19 infection and transient fetal hydrops. Lancet 337: 496.PubMedCrossRefGoogle Scholar
  51. Moroff G, Benade LE, Dabey M (1989) Use of photochemical procedures to inactivate viruses in platelet suspensions. Transfusion 29: 15 abst.Google Scholar
  52. Neyndorff HC, Bartel DL, Tufaro F (1990) Development of a model to demonstrate photosensitizer mediated viral inactivation in blood. Transfusion 30: 485–490.PubMedCrossRefGoogle Scholar
  53. Nilsson IM, Berntrorp E, Ljung R (1990) Hepatitis C virus transmission by monoclonal antibody purified factor VIII concentrate. Lancet 335: 1531–1532.PubMedGoogle Scholar
  54. Ochs HD, Fischer SH, Virant FS (1985) Non-A, Non-B hepatitis and iv immunoglobulin. Lancet i: 404–405.CrossRefGoogle Scholar
  55. Oshiro LS, Dondero DV, Emmons RW (1978). The development of Colorado tick fever virus within cells of the hematopoetic system. J Gen Virol 39: 73–79.PubMedCrossRefGoogle Scholar
  56. Perdrau JR, Todd C (1933) The photodynamic action of methylene blue on certain viruses. Proc Roy Soc B 112: 288–298.CrossRefGoogle Scholar
  57. Piet MPJ, Chin S, Prince AM (1990) The use of TNBP detergent mixtures to inactivate hepatitis viruses and HIV in plasma. Transfusion 30: 591–598.PubMedCrossRefGoogle Scholar
  58. Piszkiewicz D, Sun CS, Tondreau SC (1989) Inactivation and removal of human immundeficiency virus in monoclonal purified antihemophilic factor. Thromb Res. 55: 627–634.PubMedCrossRefGoogle Scholar
  59. Piszkiewicz D. Tondreau SC (1990) Inactivation of HIV-2 by solvent/detergent treatment. Transfusion 30: 192.PubMedCrossRefGoogle Scholar
  60. Preiksaitis JK (1991) Indications for the use of cytomegalovirus-seronegative blood products. Transf Med Rev 5: 1–17.CrossRefGoogle Scholar
  61. Prince AM, Horowitz B, Horowitz MS (1987) The development of virus free labile blood derivatives. Eur J Epidemiol 3: 103–118 REVIEW.PubMedGoogle Scholar
  62. Prodouz KN, Fratantoni JC, Boone EJ (1987) Use of laser-uv inactivation of virus in blood products. Blood 70: 589–592.PubMedGoogle Scholar
  63. Prodouz KN, Fratantoni JC (1988) Inactivation of virus in blood products. Transfusion 28: 2–3.PubMedCrossRefGoogle Scholar
  64. Roussel RH, Budinger MD, Pirofsky B (1991) Prospective study on the hepatitis safety of iv Immunoglobulin, pH 4.25. Vox Sang 60: 65–68.CrossRefGoogle Scholar
  65. Review (1988) Ways to reduce the risk of transmission of viral infections by plasma and plasma products. Vox Sang 54: 228–245CrossRefGoogle Scholar
  66. Rubinstein AI, Rubinstein DB (1989) Thermal inactivation by sequential dry-heat treatments at sterilizing temperatures of factor VIII and factor IX concentrates to produce sterile concentrates. Vox Sang 57: 272.PubMedCrossRefGoogle Scholar
  67. Schimpf K, Mannucci PM, Kreutz W (1987) Absence of hepatitis after treatment with a pasteurized factor VIII concentrate in patients with hemophilia and no previous transfusions. NEJM 316: 918–922.PubMedCrossRefGoogle Scholar
  68. Schmitt (1990) Personal communication.Google Scholar
  69. Sieber F, Spivak JL, Sutcliffe AM (1984) Selective killing of leukemic cells by merocyanine 540 mediated photosensitization. Proc Natl Acad Sci 81: 7584–7587.PubMedCrossRefPubMedCentralGoogle Scholar
  70. Sieber F (1987) Yearly review: merocyanine 540. Photochem Photobiol 46: 1035–1042.PubMedCrossRefGoogle Scholar
  71. Sieber F, Krueger GJ, o’Brien JM (1989) Inactivation of Friend erythroleukemia virus and Friend virus-transformed cells by merocyanine 540 mediated photosensitization. Blood 73: 345–350.PubMedGoogle Scholar
  72. Singer CRJ, Azim T, Sattentau Q (1988) Preliminary evaluation of phthalocyanine photosensitization for inactivation of viral pathogens in blood products. Br J Hematol 69: 111 abstr.Google Scholar
  73. Snipes W, Person S, Keller G (1977) Inactivation of lipid containing viruses by long chain alcohols. Antimicrob Agents chemoth 11: 98–104.CrossRefGoogle Scholar
  74. Snyder E, Beardsley D, Smith B (1989) Storage of platelet concentrates after UV irradiation. Blood 74: 179 abstr.Google Scholar
  75. Stephan W (1988) Virusinaktivierung von Blutprodukten. In: G. Maass (ed) Virussicherheit von Blut, Plasma und Plasmaprodukten. Springer-Verlag S. 53–61.Google Scholar
  76. Thoma KB, Mcgrath KM, Taylor M (1988) Effect of virucidal heat treatment on proteins in human factor VIII concentrates. Transfusion 28: 8–13.CrossRefGoogle Scholar
  77. Uemara Y, Yikoyama K, Nishida M, Suyama T (1989) Immunoglobulin preparations: safe from virus transmission? Vox Sang 57: 1–3.CrossRefGoogle Scholar
  78. Van der Zee J, Tijssen CK, Dubbelman TMAR (1987) The influence of ozone on human red blood cells. Biochem Biophys acta 924: 111–118.PubMedCrossRefGoogle Scholar
  79. Vaughn JM, Chen YS, Lindburg K (1987) Inactivation of human and simian rotaviruses by ozone. Appl Environ Microbiol 53: 2218–2221.PubMedPubMedCentralGoogle Scholar
  80. Wagner KF, Mayers DL, Linette GP (1989) Effect of ozone of HIV in experimentally infected blood. CDC Aids weekly Jan 30: 17.Google Scholar
  81. Wagner SJ, Friedman LI, Dodd RY (1991) Approaches to the reduction of viral infectivity in cellular blood components and single donor plasma. Transfusion Medicine Reviews 5: 18–32. REVIEWPubMedCrossRefGoogle Scholar
  82. Weiland O, Mattson L, Glaumann H (1986) Non-A, Non-B hepatitis after iv gammaglobulin. Lancet i: 975–977.Google Scholar
  83. Williams B, Horowitz B, Geacintov N (1988) Inactivation of viruses in cellular blood products. Blood 72: 287 abst.Google Scholar
  84. Williams PE, Yap PL, Gillon J (1989) Transmission of Non-A, Non-B Hepatitis by pH 4 treated iv Immunoglobulin. Vox Sang 57: 15–18.PubMedCrossRefGoogle Scholar
  85. Winkelman L, Owen NE, Evans DR (1989) Severely heated therapeutic factor VIII concentrate of high specific activity. Vox Sang 57: 97–103.PubMedCrossRefGoogle Scholar
  86. Zuck TF (1987) Greetings — a final look back with comments about a policy of a zero-risk blood supply. Transfusion 27: 447–448.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1992

Authors and Affiliations

  • U. T. Seyfert
  • W. Hauck
  • M. Köhler
  • E. Wenzel

There are no affiliations available

Personalised recommendations